Interpretation of the latest market reference price of pitobrutinib/pirtobrutinib in 2025

Pirtobrutinib (pirtobrutinib), as a selective non-covalent BTK inhibitor, has received great attention in the field of hematological cancer treatment, but its price is still the biggest concern for patients. The latest market in 2025 shows that the original drug has been launched in China, and it can also be reimbursed through medical insurance in 2026. At present, 100mg14 tablets of 4 are sold in domestic hospitals and formal channels. The price per box is about more than 40,000 yuan, which puts great economic pressure on long-term treatment patients and also affects the accessibility of some patients.

In overseas markets, the original drug of pitubrutinib is more expensive. The European version and the American version are the two most common imported specifications. Among them, 50mg 30 tablets and 100mg 60 tablets are the mainstream packaging, with each box selling for nearly 100,000 yuan. Since international drug prices are affected by R&D costs, market size, and regional taxes and fees, overseas original drug prices are generally much higher than domestic levels. Therefore, many patients choose to look for more economical alternatives, but they must also ensure that the channels are formal to avoid purchasing counterfeit or improperly stored medicines.

With the increase in demand, some overseas countries have launched generic versions of pitobrutinib (pirtobrutinib) to provide patients with more choices. 50mg30 tablets produced by Laos Pharmaceutical Factory are the most common in the market. The latest price is about more than 2,000 yuan. Compared with the original drug, the cost is significantly lower. The drug ingredients are basically the same as the original drug. Therefore, it has attracted attention among patients with heavy financial burden. However, the quality of generic drugs depends on the compliance of manufacturers, and patients should choose channels with formal batch numbers, legal registration and stable supply chains.

Overall,2025The price difference of pitubrutinib is obvious: the domestic original drug is more than 40,000 yuan per box, the overseas original drug is as high as about 100,000 yuan, while the Laotian generic version only costs a few thousand yuan. Although generic drugs have an advantage in price, patients still need to consider their own condition, financial affordability and doctor's advice when choosing. Whether original research or imitations, they should be obtained through formal channels to ensure reliable sources and controllable quality of drugs, thereby ensuring therapeutic effects and medication safety.

Reference materials:https://go.drugbank.com/drugs/DB17472